Table 4.
Liver injury following anti-TB treatment in the study subjects
| Therapy for 2 W | Therapy for 4 W | Therapy for 8 W | ||||
|---|---|---|---|---|---|---|
|
|
||||||
| Result | Experimental group (%) | Control group (%) | Experimental group (%) | Control group (%) | Experimental group (%) | Control group (%) |
| No function abnormalities | 230 (83.03) | 233 (80.07) | 229 (82.67) | 214 (73.54) | 226 (81.59) | 215 (73.88) |
| Abnormal function | 27 (9.75) | 33 (11.34) | 26 (9.39) | 40 (13.75) | 21 (7.58) | 33 (11.34) |
| Mild injury | 6 (2.17) | 7 (2.41) | 3 (1.08) | 6 (2.06) | 1 (0.36) | 0 (0.00) |
| Moderate injury | 5 (1.81) | 2 (0.69) | 1 (0.36) | 3 (1.03) | 5 (1.81) | 6 (2.06) |
| Severe injury | 0 (0.00) | 3 (1.03) | 0 (0.00) | 3 (1.03) | 0 (0.00) | 1 (0.34) |
| Liver failure | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Undetermined | 9 (3.25) | 13 (4.47) | 18 (6.50) | 25 (8.59) | 24 (8.66) | 36 (12.37) |
| The overall incidence of liver injury | 11 (3.97) | 12 (4.12) | 4 (1.44) | 12 (4.12) | 6 (2.17) | 7 (2.41) |
| Statistics | 4.801 | 8.386 | 5.024 | |||
| P | 0.308 | 0.078 | 0.285 | |||
Note: The groups were compared using the Wilcoxon test.